Literature DB >> 27521014

Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.

A Dalvi1, B Ford2.   

Abstract

The treatment of Parkinson's disease for most patients entails long term exposure to multiple agents, including anticholinergics, levodopa, amantadine, dopamine receptor agonists, catechol-O-methyltransferase inhibitors, selegiline (deprenyl) and clozapine. Patients with Parkinson's disease require medication for the control of the motor symptoms of their condition, for related medical or psychiatric symptoms of the disorder, and for concurrent medical problems, such as hypertension or cardiac disease.All these agents may cause adverse effects. There is a potential for drug-drug interactions between different antiparkinsonian agents and between antiparkinsonian medication and the other drugs a patient may be taking. Clinicians caring for patients with Parkinson's disease must be knowledgable about the potential adverse effects and drug interactions of an expanding array of medications for this condition.

Entities:  

Year:  1998        PMID: 27521014     DOI: 10.2165/00023210-199809040-00005

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  119 in total

1.  Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium.

Authors:  L Tune; S Carr; E Hoag; T Cooper
Journal:  Am J Psychiatry       Date:  1992-10       Impact factor: 18.112

2.  Apparent neuroleptic malignant syndrome with clozapine and lithium.

Authors:  H G Pope; J O Cole; P T Choras; C E Fulwiler
Journal:  J Nerv Ment Dis       Date:  1986-08       Impact factor: 2.254

3.  Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine.

Authors:  M V Nelson; R C Berchou; D Kareti; P A LeWitt
Journal:  Clin Pharmacol Ther       Date:  1990-06       Impact factor: 6.875

Review 4.  The management of the levodopa psychoses.

Authors:  J H Friedman
Journal:  Clin Neuropharmacol       Date:  1991-08       Impact factor: 1.592

5.  Parkinsonism induced by amlodipine.

Authors:  A P Sempere; J Duarte; C Cabezas; F Coria; L E Clavería
Journal:  Mov Disord       Date:  1995-01       Impact factor: 10.338

6.  Possible development of the serotonin syndrome in man.

Authors:  T R Insel; B F Roy; R M Cohen; D L Murphy
Journal:  Am J Psychiatry       Date:  1982-07       Impact factor: 18.112

Review 7.  Antiparkinsonian agents. Drug interactions of clinical significance.

Authors:  R F Pfeiffer
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

8.  Persistent movement disorders induced by buspirone.

Authors:  P A LeWitt; A Walters; W Hening; D McHale
Journal:  Mov Disord       Date:  1993-07       Impact factor: 10.338

9.  Psychotic complications of long-term levodopa treatment of Parkinson's disease.

Authors:  A Friedman; J Sienkiewicz
Journal:  Acta Neurol Scand       Date:  1991-08       Impact factor: 3.209

10.  Flunarizine- and cinnarizine-induced extrapyramidal reactions.

Authors:  F Micheli; M F Pardal; M Gatto; M Torres; G Paradiso; I C Parera; R Giannaula
Journal:  Neurology       Date:  1987-05       Impact factor: 9.910

View more
  3 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 2.  Clinical pharmacokinetics of ropinirole.

Authors:  C M Kaye; B Nicholls
Journal:  Clin Pharmacokinet       Date:  2000-10       Impact factor: 6.447

3.  Treatment paradigms in Parkinson's Disease and Covid-19.

Authors:  Iro Boura; Lucia Batzu; Espen Dietrichs; Kallol Ray Chaudhuri
Journal:  Int Rev Neurobiol       Date:  2022-05-28       Impact factor: 4.280

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.